Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0M7LQ
|
||||
Former ID |
DCL000742
|
||||
Drug Name |
CBD cannabis derivative
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Discontinued in Phase 1 | [536463] | ||
Company |
GW Pharmaceuticals
|
||||
Structure |
Download2D MOL |
||||
Formula |
C33H53NO3
|
||||
Canonical SMILES |
CCCCCCCC(C)C1=CC2=C(C3=C(CCCC3)C(O2)(C)C)C(=C1)OC(=O)CC<br />CCN(CC)CC
|
||||
InChI |
1S/C33H53NO3/c1-7-10-11-12-13-18-25(4)26-23-29(36-31(35)21-16-17-22-34(8-2)9-3)32-27-19-14-15-20-28(27)33(5,6)37-30(32)24-26/h23-25H,7-22H2,1-6H3
|
||||
InChIKey |
LKZQTNSAWVCNMU-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Cannabinoid receptor 1 | Target Info | Antagonist | [536463] | |
PANTHER Pathway | Endogenous cannabinoid signaling | ||||
Pathway Interaction Database | N-cadherin signaling events | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.